Institute of Integrated Traditional Chinese and Western Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 430030, China.
Department of Traditional Chinese Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095 Jiefang Avenue, Wuhan, Hubei, 430030, China.
J Ovarian Res. 2023 Jul 31;16(1):149. doi: 10.1186/s13048-023-01236-9.
Polycystic ovary syndrome (PCOS) is known as a prevalent but complicated gynecologic disease throughout the reproductive period. Typically, it is characterized by phenotypic manifestations of hyperandrogenism, polycystic ovary morphology, and persistent anovulation. For now, the therapeutic modality of PCOS is still a formidable challenge. Metabolic aberrations and immune challenge of chronic low-grade inflammatory state are significant in PCOS individuals. Recently, interleukin-22 (IL-22) has been shown to be therapeutically effective in immunological dysfunction and metabolic diseases, which suggests a role in the treatment of PCOS. In this review, we outline the potential mechanisms and limitations of IL-22 therapy in PCOS-related metabolic disorders including its regulation of insulin resistance, gut barrier, systemic inflammation, and hepatic steatosis to generate insights into developing novel strategies in clinical practice.
多囊卵巢综合征（PCOS）是一种常见但复杂的妇科疾病，存在于整个生育期。通常，其特征表现为高雄激素血症、多囊卵巢形态和持续性无排卵。目前，PCOS 的治疗方法仍然是一个巨大的挑战。代谢异常和慢性低度炎症状态的免疫挑战在 PCOS 个体中非常显著。最近，白细胞介素 22（IL-22）已被证明在免疫功能障碍和代谢疾病方面具有治疗效果，这表明其在治疗 PCOS 方面具有一定作用。在这篇综述中，我们概述了 IL-22 治疗 PCOS 相关代谢紊乱的潜在机制和局限性，包括其对胰岛素抵抗、肠道屏障、全身炎症和肝脂肪变性的调节，以期为临床实践中开发新策略提供思路。
